Skip to content
Shorla Oncology: A Leader in Innovative Oncology Solutions
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Company Updates

Maurice_Orlaith Bioequity

Shorla Oncology at BioEquity Europe 2023 in Dublin

May 16th 2023

Read More

Banner

Shorla Oncology & EVERSANA Announce Commercial Launch of Recent FDA-Approved Nelarabine Injection

May 16th 2023

Read More

OKs

Step Challenge for Oscars Kids!

April 25th 2023

Read More

Banner

Shorla Oncology will be attending Asembia’s ASX Summit in Las Vegas

April 17th 2023

Read More

Banner

Our CEO to speak at BioEquity: Europe 2023 in Dublin on May 14-16, 2023

March 23rd 2023

Read More

Banner

Shorla Oncology Announces U.S. FDA Approval of Nelarabine Injection for the Treatment of T-Cell Leukemia

March 9th 2023

Read More

Banner

We were delighted to have been a presenting company at the BIOTECH Showcase 2023 in San Francisco recently!

January 16th 2023

Read More

banner

Join Shorla Oncology at the BIO CEO and Investor Conference 2023

January 17th 2023January 16th 2023

Read More

Shorla Oncology

Join Shorla Oncology at the Biotech Showcase 2023

January 5th 2023

Read More

Older posts
Newer posts
Page1 … Page5 Page6 Page7 … Page12
Logo

IRELAND HQ:
Questum Acceleration Center,
Ballingarrane Science & Technology Park,
Clonmel, Co. Tipperary,
E91 V329, Ireland

Shorla Pharma Ltd trading as Shorla Oncology®

All trademarks are the property of their respective owners.

US OFFICE:
245 Main St.,
2nd floor,
Cambridge,
MA 02142, USA

SITEMAP

PRIVACY POLICY

CALIFORNIA COMPLIANCE PROGRAM DECLARATION

Company number: 618033
©SHORLA ONCOLOGY® 2025

© 2025 Shorla Oncology: A Leader in Innovative Oncology Solutions • Built with GeneratePress
  • About Us
    • Executive Team
    • Leadership Team
    • Board of Directors
    • Advisory Team
  • Products
    • TEPYLUTE
    • IMKELDI
    • JYLAMVO
    • Nelarabine Injection
  • Pipeline
  • News
    • Company Updates
    • Media
  • Careers
  • Contact

Now approved for use in Pediatrics

  • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA).
  • Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen.

Please click here for the full Prescribing information, including Boxed Warning regarding embryo-fetal toxicity, hypersensitivity reactions, and severe adverse reactions.